Therapeutic strategies for COVID-19: progress and lessons learned

G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Metformin: update on mechanisms of action and repurposing potential

M Foretz, B Guigas, B Viollet - Nature Reviews Endocrinology, 2023 - nature.com
Currently, metformin is the first-line medication to treat type 2 diabetes mellitus (T2DM) in
most guidelines and is used daily by> 200 million patients. Surprisingly, the mechanisms …

Infectious Diseases Society of America Guidelines on the treatment and management of patients with COVID-19 (April 2020)

A Bhimraj, RL Morgan, AH Shumaker… - Clinical Infectious …, 2024 - academic.oup.com
Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …

[HTML][HTML] Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind …

CT Bramante, JB Buse, DM Liebovitz… - The Lancet Infectious …, 2023 - thelancet.com
Summary Background Post-COVID-19 condition (also known as long COVID) is an
emerging chronic illness potentially affecting millions of people. We aimed to evaluate …

Therapeutics for COVID-19

SS Toussi, JL Hammond, BS Gerstenberger… - Nature …, 2023 - nature.com
Vaccines and monoclonal antibody treatments to prevent severe coronavirus disease 2019
(COVID-19) illness were available within a year of the pandemic being declared but there …

An overview on the treatments and prevention against COVID-19

Y Panahi, AM Gorabi, S Talaei, F Beiraghdar… - Virology Journal, 2023 - Springer
Background The coronavirus disease 2019 (COVID-19) caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to plague the world. While …

COVID-19 therapeutics

D Focosi, M Franchini, F Maggi… - Clinical microbiology …, 2024 - journals.asm.org
Since the emergence of COVID-19 in 2020, an unprecedented range of therapeutic options
has been studied and deployed. Healthcare providers have multiple treatment approaches …

Effect of higher-dose ivermectin for 6 days vs placebo on time to sustained recovery in outpatients with COVID-19: a randomized clinical trial

S Naggie, DR Boulware, CJ Lindsell, TG Stewart… - Jama, 2023 - jamanetwork.com
Importance It is unknown whether ivermectin, with a maximum targeted dose of 600 μg/kg,
shortens symptom duration or prevents hospitalization among outpatients with mild to …

Signaling pathways in macrophages: molecular mechanisms and therapeutic targets

M Li, M Wang, Y Wen, H Zhang, GN Zhao, Q Gao - MedComm, 2023 - Wiley Online Library
Macrophages play diverse roles in development, homeostasis, and immunity. Accordingly,
the dysfunction of macrophages is involved in the occurrence and progression of various …

[HTML][HTML] Bone marrow mesenchymal stem cell-derived extracellular vesicle infusion for the treatment of respiratory failure from COVID-19: a randomized, placebo …

AL Lightner, V Sengupta, S Qian, JT Ransom, S Suzuki… - Chest, 2023 - Elsevier
Background Bone marrow mesenchymal stem cell (BM-MSC)-derived extracellular vesicles
(ExoFlo) convey the immunomodulatory and regenerative properties of intact BM-MSCs …